Niagen Bioscience, Inc. (NAGE)
| Market Cap | 271.36M -63.9% |
| Revenue (ttm) | 130.42M +20.8% |
| Net Income | 18.64M +32.1% |
| EPS | 0.21 +17.3% |
| Shares Out | 79.81M |
| PE Ratio | 16.19 |
| Forward PE | 19.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 648,500 |
| Open | 3.320 |
| Previous Close | 3.320 |
| Day's Range | 3.210 - 3.410 |
| 52-Week Range | 3.115 - 11.290 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+267.65%) |
| Earnings Date | Aug 4, 2026 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-gra... [Read more]
Financial Performance
In 2025, Niagen Bioscience's revenue was $129.42 million, an increase of 29.95% compared to the previous year's $99.60 million. Earnings were $17.38 million, an increase of 103.30%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 267.65% from the latest price.
News
Niagen Bioscience announces publication on muscle epigenetic age
Niagen Bioscience (NAGE) announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen supplementation was associated with reduced mu...
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BiologicalAge--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy a...
Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience price target lowered to $11 from $12 at Ladenburg
Ladenburg lowered the firm’s price target on Niagen Bioscience (NAGE) to $11 from $12 and keeps a Buy rating on the shares.
Niagen Bioscience appoints Kale as Senior Director of Global External Research
Niagen Bioscience (NAGE) announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead Niagen Bioscience’s Global Niagen...
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience Transcript: Fireside chat
The discussion highlighted the company's expansion into pharmaceutical development with NB4168, a novel NAD analog targeting rare genetic diseases and accelerated aging. The team emphasized strong scientific leadership, a robust safety profile for NB4168, and a continued focus on profitability and responsible growth.
Niagen Bioscience Slides: Corporate presentation
Niagen Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168
Niagen Bioscience (NAGE) announced that the U.S. Food & Drug Administration, FDA, granted Rare Pediatric Disease, RPD, Designation for its proprietary lead small molecule drug candidate NB4168 for the...
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
Niagen Bioscience (NAGE) formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases....
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Phar...
Niagen Bioscience initiated with a Buy at Freedom Broker
Freedom Broker analyst Ilya Zubkov initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $9 price target The firm calls Niagen “a beneficiary of powerful secular tailwinds,” including…
Niagen Bioscience Registration statement: Registration filing
Niagen Bioscience filed a registration statement on June 29, 2026, providing details about a securities offering with the SEC.
Niagen Bioscience files $125M mixed securities shelf
06:22 EDT Niagen Bioscience (NAGE) files $125M mixed securities shelf
Niagen Bioscience Transcript: 16th Annual East Coast IDEAS Conference
The company leverages proprietary NAD technology and a strong research foundation to drive growth across supplements, injectables, and skincare, reporting robust financials and expanding through strategic partnerships. New product launches and clinical progress in orphan diseases support future opportunities.
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience renames CERP to Niagen Research Program
Niagen Bioscience (NAGE) announced the official renaming of the ChromaDex External Research Program, CERP, to the Niagen Research Program, reflecting the Company’s name evolution with a focus on advan...
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Niagen Bioscience (NAGE) to $11 from $12 and keeps a Buy rating on the shares. The company reported moderate revenue outperformance with…
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience price target lowered to $12 from $13 at Roth Capital
Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $12 from $13 and keeps a Buy rating on the shares. The company’s Q1 results exceeded consensus estimates…
Niagen Bioscience reports Q1 EPS 7c, consensus 6c
Reports Q1 revenue $31.5M, consensus $31.03M. The company said, “We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter. Our results reflect continued…